ACT News 223.05 07/01/2014 04:22:57 Actavis Inc (ACT)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Actavis Inc (ACT) 223.05 $ACT

Actavis and Forest Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Forest
Business Wire - Mon Jun 30, 4:15PM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that the U.S. Federal Trade Commission (FTC) has voted to approve Actavis' proposed acquisition of Forest. The vote in support of the transaction follows Actavis and Forest's agreement to a proposed consent order, pursuant to which the companies have agreed to divest certain products as a condition to obtaining FTC approval. The closing of the transaction remains subject to other customary closing conditions, and is expected to be effective on July 1, 2014.

Actavis and Forest Announce Preliminary Stockholder Merger Consideration Election Results
Business Wire - Mon Jun 30, 7:30AM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced the preliminary results of the elections made by stockholders of Forest regarding their preference as to the form of merger consideration they will receive in connection with Actavis' pending acquisition of Forest. Subject to regulatory approval and other customary closing conditions, the closing of the acquisition is expected to be effective on July 1st, 2014.

Actavis to Host Second Quarter 2014 Earnings Conference Call and Webcast
PR Newswire - Mon Jun 30, 7:00AM CDT
Actavis plc (NYSE: ACT) today announced that it intends to release second quarter 2014 financial results on Tuesday, August 5, 2014, prior to the open of the U.S. financial markets. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, August 5, 2014 to discuss its financial results. The dial-in number to access the call is U.S./Canada (877) 251-7980, International (706) 643-1573, and the Conference ID is 65351447.

Actavis Confirms Generic Zubsolv® Patent Challenge
PR Newswire - Mon Jun 30, 6:30AM CDT
Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, Eq, 1.4 mg/0.36 mg and 5.7 mg/1.4 mg Base. Actavis' ANDA product is a generic version of Orexo's Zubsolv®, which is a partial opioid agonist indicated for the maintenance treatment of opioid dependence.

Many IBD 50 Stocks Struggle To Climb After Breakouts
at Investor's Business Daily - Fri Jun 27, 6:08PM CDT
A number of IBD 50 stocks have cleared buy points recently, but many of them have made little progress. Noneof the stocks is flashing a sell signal, but many of the bases are riskier late-stage patterns. As a result, investors should remain vigilant,...

Auxilium and QLT to Merge on Tax Saving Attractions - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 11:10AM CDT
Auxilium (AUXL) and QLT (QLTI) will combine by year end.

Novo, Other Medicals Display Healthy Action
at Investor's Business Daily - Thu Jun 26, 5:41PM CDT
Leaders in buy range could get tougher to find as the market uptrend continues and stocks break out to new highs. But a raft of medical plays in today's Your Weekly Review are showing fairly healthy action as they work on bases or move near buy...

Leadership Appointments, Approved Acquisitions, Licensing Agreements, Technical UPdate, and Response to Tender Offer Announcement - Analyst Notes on Actavis, Forest, Vertex, MannKind and Gentiva
PR Newswire - Thu Jun 26, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Forest Laboratories Inc. (NYSE: FRX), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), MannKind Corp. (NASDAQ: MNKD) and Gentiva Health Services Inc. (NASDAQ: GTIV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4129-100free.

World Market for Pain Management Drugs and Devices to 2017
M2 - Thu Jun 26, 2:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xbzv4k/the_world_market) has announced the addition of the "The World Market for Pain Management Drugs and Devices" report to their offering. The World Market for Pain Management Drugs and Devices encompasses a wide variety of products that treat and ease pain. The field of pain management is currently experiencing a busy and interesting period; and as a result, the range of therapeutic options available to physicians and other clinicians has expanded. Solutions to pain disorders are still elusive but continued human and animal studies will help to further identify the biochemical and neurophysiological factors that influence pain. The future of pain management will likely involve multidisciplinary departments dedicated to finding treatments that manage pain. The need is great worldwide for management of pain and there are still many facets of pain management that need to be explored. Faced with intensifying competition and increasingly price sensitive markets, manufacturers in the area of pain management therapeutics are trying to differentiate their products to avoid price competition and to increase profits. However, there are a number of issues and trends that have a direct influence on this market and the manufacturer's ability to successfully operate in the market. A keen awareness of all facets of the industry including barriers will enable manufacturers to effectively challenge these issues and formulate plans to reduce or eliminate barriers in the treatment of pain. The driving forces for this market include growth and aging of the global population, new products and technology, and increasing interest in multidisciplinary approaches to pain management. The World Market for Pain Management Drugs and Devices, provides market estimates and forecasts for the following therapeutic categories: - Burn Pain - Cancer Pain - Dental/Facial Pain - Migraine Headache Pain - Musculoskeletal Pain - Neuropathic Pain - Obstetrical Pain - Pediatric Pain - Surgical and Trauma Pain This report details the various categories of top prescription pain management drugs, describes U.S., European, Japanese and other markets in each of the specific pain areas. The report also covers drug delivery methods, pain management devices, and alternate treatment modalities that are influencing the market. It further identifies major market factors, which are discussed, and a total market summary is presented. As part of the study the following competitors are profiled: - Abbott Laboratories - Actavis, Inc (formerly Watson Pharmaceuticals, Inc.) - AstraZeneca plc. - Baxter International, Inc. - BioDelivery Sciences International (BDSI) - Boehringer Ingelheim - Boston Scientific - Bristol-Myers Squibb Company - DepoMed - DURECT Corporation - Eli Lilly & Co. - Endo Health Solutions Inc - GlaxoSmithKline plc - Grunenthal Group - Medtronic, Inc. - Merck & Co. - Novartis - Pain Therapeutics, Inc - Pfizer, Inc - Purdue Pharma - QRx Pharma - Sanofi - St. Jude Medical, Inc - TEVA Pharmaceuticals Industries, Ltd - The Medicines Company - Valeant Pharmaceuticals International, Inc. - Zogenix, Inc. For more information visit http://www.researchandmarkets.com/research/xb...rld_market

Endo International to Expand Generics Business with DAVA Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 2:20PM CDT
Endo (ENDP) has inked a deal to buy DAVA Pharmaceuticals for a cash consideration of approximately $575 million.

Love the Stocks Everyone Hates: 5 Short-Squeeze Stocks Ready to Pop
at The Street - Wed Jun 25, 9:34AM CDT
These heavily shorted stocks could get squeezed on any positive catalyst.

Affiliated Managers Group Set to Join S&P 500; LaSalle Hotel Properties, Rayonier Advanced Materials, TimkenSteel, Belden to Join the S&P MidCap 400; Others to Join S&P SmallCap 600
PR Newswire - Tue Jun 24, 5:50PM CDT
S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices:

Forest Laboratories Reports Positive Data on Viibryd - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 5:20PM CDT
Forest Laboratories, Inc. (FRX) announced positive top-line results from three phase III trials evaluating the efficacy, safety and tolerability of Viibryd in adults suffering from generalized anxiety disorder.

Are Investors Wrong About VIVUS?
George Budwell, The Motley Fool - Motley Fool - Tue Jun 24, 4:30PM CDT
Whenever short-sellers start jumping into a stock with both feet, it's generally a good idea to understand why.  VIVUS has seen its short interest skyrocket this year to over 35% of the float, while the company's share price has subsequently...

Actavis and Forest Announce Tentative Election Deadline of June 27, 2014
Business Wire - Tue Jun 24, 7:30AM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that the tentative election deadline for Forest stockholders to elect the form of consideration they wish to receive in Actavis' planned acquisition of Forest is 5:00 p.m., Eastern time, on June 27, 2014 (the "Election Deadline" . The Election Deadline may be extended, in which case Actavis and Forest will issue a press release announcing the new election deadline. Subject to regulatory approval and other customary closing conditions, the closing date of the acquisition is expected to be July 1, 2014. Forest stockholders who hold shares through a bank, broker, trust company or other nominee may have an earlier election deadline and should carefully review any instructions received from their bank, broker, trust company or other nominee.

Major Indexes Narrowly Lower As Actavis Rallies
at Investor's Business Daily - Mon Jun 23, 12:29PM CDT
Despite better-than-expected economic data, the major averages were still trading flat to slightly lower in early-afternoon trading. The Nasdaq was flat, while the S&P 500 edged down 0.1% and the Dow industrials eased 0.2%. Volume was tracking well...

3 Stocks Driving The Health Care Sector Higher
at The Street - Mon Jun 23, 12:09PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

HLTH USA 2026 Spotlights AI and Health Innovation

Updated Category News Views 12

The Pulse of Innovation at HLTH USA 2026 Diving headfirst into the heart of healthcare innovation, HLTH USA 2026 kicked off with gusto in Las Vegas. Discussions are swirling around AI advancements and the next generation of payer-provider collaboration. Who knew healthcare could be this thrilling? The event is already shaping up to be a powerhouse of change, buzzing with...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 44

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 59

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading
WHP Global's Japan Move: A Major Toy Market Play

Updated Category News Views 0

New Horizons for Toys"R"Us in Japan Well, folks, look who's back in the toy game with a vengeance! WHP Global is shaking hands with Pan Pacific International Holdings (PPIH) to breathe new life into Toys"R"Us across Japan. Now PPIH isn’t just any player. We're talking about Japan's fourth-largest retailer, helming giants like Don Quijote and aiming to crown itself as...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 64

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 149

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
Univers Partners to Propel Physical AI Across Industries

Updated Category News Views 95

Univers Sets Sights on Global Physical AI Expansion Now here's a tune we've been humming for a while—AI is coming to take over the mundane, and Univers seems to think it's got the right band together to make that a full-blown concert in the built environment. Announced right in the heart of Antalya, Türkiye, at the esteemed COP31, we're seeing Univers grab hands with...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 115

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Engrain's Geospatial Innovation Pushes Property Mapping Forward

Updated Category News Views 45

Pushing the Boundaries of Property Mapping How far can you expand the boundaries of property mapping tech? Well, Engrain seems hell-bent on finding out by cranking their innovations up a notch. The Denver-based stalwart in interactive mapping is rolling out some mind-boggling enhancements that could redefine how the multifamily housing sector operates. This isn't just...

Continue Reading
Dawson Struggles With Q3 Losses Despite Growth Prospects

Updated Category News Views 25

Profit and loss dance around like a jittery stock, and Dawson Geophysical is feeling the heat this third quarter. Numbers are in, and we’re seeing a net loss of $5.2 million, translating to $0.17 per share—ouch. Not to mention a negative Adjusted EBITDA of $2 million. Compared to last year's hopes, that's a serious belly flop. Revenue Down, Hopes Up In a fetching...

Continue Reading

Top 5 Most Recently Viewed Articles

BD Unveils Advanced Hemodynamic Monitoring Solution to Aid Clinicians

Updated Category News Views 225

Revolutionizing Patient Monitoring with AI Technology BD (Becton, Dickinson and Company) (NYSE: BDX) has introduced a groundbreaking hemodynamic monitoring solution known as the HemoSphere Alta™ Advanced Monitoring Platform. This innovative system incorporates predictive algorithms powered by artificial intelligence (AI), designed to assist clinicians in managing blood...

Continue Reading
James Talarico's Bold Stand Against Elon Musk's Pay Package

Updated Category News Views 395

Texas Representative James Talarico's Critique of Billionaire Wealth Rep. James Talarico from Texas has recently made headlines with his pointed criticism of Tesla's CEO, Elon Musk, regarding the approval of his staggering new trillion-dollar compensation package. Talarico emphasized the pressing issue of income disparity in the wealthiest nation. The Inequity in Wealth...

Continue Reading
Priority Technology Holdings, Inc. Reaches New Heights in Market

Updated Category News Views 84

Recent Surge in Priority Technology Holdings Stock Priority Technology Holdings, Inc. (PRTH) has made headlines recently as its stock reached a remarkable 52-week high, hitting $9.89. This surge exemplifies a dramatic turnaround for the company, with its stock value experiencing a striking climb over the past year. Investors have been vigilant about PRTH's trajectory, and...

Continue Reading
Lokal Homes Unveils Exciting New Lots in Jackson Creek Community

Updated Category News Views 272

Introducing New Homes at Jackson Creek Lokal Homes, a renowned homebuilder in Colorado, is thrilled to announce the upcoming launch of its latest community, Jackson Creek. Nestled in stunning foothills, this new community promises to bring exceptional living spaces to prospective homebuyers. The grand opening is set for a future date, and it is already generating...

Continue Reading
Understanding the Drop in Hims & Hers Health Stock Today

Updated Category News Views 89

The Factors Behind Hims & Hers Health's Stock Decline Hims & Hers Health Inc shares have faced a downturn in trading, largely influenced by market dynamics involving competitors. The decline appears to be a reaction to news surrounding Eli Lilly and Company, a major player in the pharmaceutical sector. Recent Developments with Eli Lilly Recent announcements from the U.S....

Continue Reading